X
ADMA icon

Xponance’s ADMA Biologics ADMA Stock Holding History

Xponance’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Buy
22,363
+458
+2% +$4.17K ﹤0.01% 1624
2026
Q1 		$197K Buy
21,905
+3,501
+19% +$55.3K ﹤0.01% 1477
2025
Q4 		$336K Buy
18,404
+108
+0.6% +$1.82K ﹤0.01% 1122
2025
Q3 		$268K Buy
18,296
+227
+1% +$3.89K ﹤0.01% 1220
2025
Q2 		$329K Sell
18,069
-7,878
-30% -$161K ﹤0.01% 1098
2025
Q1 		$515K Sell
25,947
-2,965
-10% -$51.3K 0.01% 922
2024
Q4 		$496K Sell
28,912
-409
-1% -$7.7K ﹤0.01% 951
2024
Q3 		$586K Buy
29,321
+10,853
+59% +$169K 0.01% 887
2024
Q2 		$206K Buy
18,468
+5,597
+43% +$47K ﹤0.01% 1173
2024
Q1 		$84.9K Sell
12,871
-132
-1% -$721 ﹤0.01% 1249
2023
Q4 		$58.8K Sell
13,003
-379
-3% -$1.4K ﹤0.01% 1232
2023
Q3 		$47.9K Buy
13,382
+226
+2% +$870 ﹤0.01% 1206
2023
Q2 		$48.5K Buy
13,156
+1,271
+11% +$4.71K ﹤0.01% 1226
2023
Q1 		$39.3K Buy
11,885
+1,296
+12% +$4.48K ﹤0.01% 1199
2022
Q4 		$41.1K Buy
10,589
+208
+2% +$642 ﹤0.01% 1191
2022
Q3 		$25K Buy
10,381
+299
+3% +$717 ﹤0.01% 1175
2022
Q2 		$20K Buy
+10,082
New +$19.8K ﹤0.01% 1181

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Xponance's ADMA Position: Q2 2026 in Review

Xponance increased its ADMA Biologics (ADMA) stake by 2.1% in Q2 2026, buying an estimated $4.17K and bringing the position to 22,363 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Xponance first reported a position in ADMA in Q2 2022 and has held it in 17 quarters since. The position peaked at $586K in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Xponance held 22,363 shares of ADMA Biologics worth $187K as of Q2 2026.
  • Xponance bought 458 ADMA Biologics shares in Q2 2026, an estimated $4.17K.
  • ADMA Biologics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1624 holding.
  • Xponance first reported a position in ADMA Biologics in Q2 2022 and has held it in 17 quarters since.
  • Xponance's ADMA Biologics position peaked at $586K in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.